Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909545 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00909545: Completed Phase 2 study, sponsored by Northwestern University.
NCT00909545 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 99 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00909545, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
Primary Outcome
Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.
Interventions
- DRUG Placebo
- DRUG Isradipine CR 5mg
- DRUG Isradipine CR 10mg
- DRUG Isradipine CR 20mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT00909545 record still lists
NCT00909545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00909545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00909545 about?
NCT00909545 is a clinical study titled "Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease". The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
What is the current status of trial NCT00909545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2009-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00909545?
The interventions under investigation include: Placebo (DRUG), Isradipine CR 5mg (DRUG), Isradipine CR 10mg (DRUG), Isradipine CR 20mg (DRUG).
Who is sponsoring clinical trial NCT00909545?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00909545's enrollment target sits among peer trials
99 738th of 2000 higher than 1,258 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia